Sangamo Therapeutics
Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.
Sangamo Therapeutics
SGMO
NASDAQ
Biotechnology company developing gene therapies and genome editing.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy targets chronic nerve pain in new trial Results expected Jul 2027 (estimated)